Search

Displaying results 4601 - 4610 of 5040 in total
  1. Drug

    Razpipadon

    go.drugbank.com/drugs/DB21542
    Investigational

    Razpipadon has a monoisotopic molecular weight of 389.12 Da.

  2. Drug

    Zatonacaftor

    go.drugbank.com/drugs/DB21625
    Experimental

    Zatonacaftor has a monoisotopic molecular weight of 453.17 Da.

  3. Drug

    Ninerafaxstat

    go.drugbank.com/drugs/DB21486
    Investigational

    Ninerafaxstat has a monoisotopic molecular weight of 415.21 Da.

  4. Drug

    Thyrotropin alfa

    go.drugbank.com/drugs/DB00024
    ApprovedInvestigationalVet approved

    The beta subunit (TSHB) bestows its receptor specificity due to the uniqueness to TSH. The amino acid sequence of thyrotropin alfa is identical to that of human pituitary thyroid stimulating hormone.

  5. Drug

    Repotrectinib

    go.drugbank.com/drugs/DB16826
    ApprovedInvestigational

    Repotrectinib is a next-generation tyrosine kinase inhibitor (TKI) specifically designed to address resistance in the treatment of non-small cell lung cancer (NSCLC), specifically due to mutations in the

  6. Drug

    Salsalate

    go.drugbank.com/drugs/DB01399
    ApprovedInvestigational

    Salsalate's mode of action as an anti-inflammatory and antirheumatic agent may be due to inhibition of synthesis and release of prostaglandins.

  7. Drug

    Protriptyline

    go.drugbank.com/drugs/DB00344
    Approved

    The antidepressant effects of TCAs are thought to be due to an overall increase in serotonergic neurotransmission.

    Synonyms: 5-(3-methylaminopropyl)-5H-dibenzo[a,d]cycloheptene, 3-(5H-dibenzo[a,d][7]annulen-5-yl)-N-methylpropan-1-amine
  8. Drug

    Lomitapide

    go.drugbank.com/drugs/DB08827
    Approved

    Lomitapide, marketed under the brand names Juxtapid (USA) and Lojuxta (EU), is a first-in-class, small-molecule inhibitor of microsomal triglyceride transfer protein (MTP).

  9. Drug

    Infigratinib

    go.drugbank.com/drugs/DB11886
    ApprovedInvestigationalWithdrawn

    [L34304] The FDA later announced the final withdrawal of the approval of infigratinib for this indication on May 16, 2024: This decision was based on the sponsor's request due to clinical trial recruitment

  10. Drug

    iCo-007

    go.drugbank.com/drugs/DB05268
    Investigational

    compound being developed by iCo for the treatment of various eye diseases caused by the formation of new blood vessels (angiogenesis) such as age-related macular degeneration (AMD) and diabetic retinopathy(DR